Current medications
A program should request an accurate list early enough for a qualified review. It should not encourage abrupt changes or give blanket instructions without knowing a person’s history and prescribing context.
Ibogaine in Rosarito · practical due diligence
Safety & Screening
A calm, non-prescriptive guide to the questions international visitors should ask about medical screening, monitoring, emergency readiness, and planning after an ibogaine stay.
Evidence-aware considerations
A starting point
Safety is a process, not a promise.
Ibogaine carries meaningful medical uncertainty and risk. For anyone considering treatment in Rosarito, a program’s screening and emergency plans matter more than broad assurances. This page is intended as a due-diligence framework, not a substitute for individualized clinical advice or a recommendation to pursue treatment.
For broader local context, begin with the Rosarito guide’s overview of practical considerations, then use these questions to evaluate whether a program describes its limits, procedures, and escalation plans clearly. A provider’s willingness to identify risk can be more informative than a confident outcome claim.
01 · Before arrival
Cardiac screening needs to be specific.
Ibogaine has been associated with changes in cardiac rhythm, including QT interval prolongation. The U.S. Food and Drug Administration notes that QT prolongation can contribute to dangerous arrhythmias in some circumstances, a concern described in its safety communication on abnormal heart rhythms.
A credible intake process should make room for a complete health history, prior cardiac events, fainting episodes, family history relevant to rhythm disorders, and a review of available records. A baseline electrocardiogram (ECG) is a practical topic to ask about: when it is performed, who reviews it, what findings trigger referral or exclusion, and whether the program has a defined approach to repeat assessment.
Programs should be able to explain how they address abnormal results rather than treating an ECG as a one-time administrative checkbox. Ask what clinical decision-making is available if an ECG, electrolyte result, or history raises concern. The scope and limits of this independent resource are described in our approach to evidence-aware information.
- Ask whether a baseline ECG and relevant laboratory review are completed before treatment is considered.
- Ask who interprets concerning findings and what circumstances lead to postponement, referral, or declining admission.
- Ask whether telemetry or another form of continuous cardiac observation is available during the period the program considers highest risk.
02 · Medication and substance review
Interactions cannot be assessed from a short list.
A careful review needs to include prescribed medicines, non-prescribed substances, supplements, recent changes, and the timing of use. This is particularly relevant for opioids, SSRIs and other antidepressants, stimulants, sedatives, and medicines that can influence cardiac rhythm or metabolism. The general pharmacology overview of ibogaine notes its active metabolite and complex effects; that complexity is a reason to expect individualized review rather than generic clearance.
Recent substance use
Ask how recent opioid, stimulant, alcohol, or other substance use is assessed, how withdrawal is handled, and when a case may require a different level of care.
Medical history
History involving the heart, liver, kidneys, seizures, breathing, or other significant conditions may change the risk picture and should be discussed directly.
03 · Supervision and escalation
Ask what happens when care becomes urgent.
Pre-treatment screening should include psychiatric history, current symptoms, prior episodes of psychosis or mania, suicidality, trauma-related concerns, and the availability of support after discharge. These questions are not a diagnosis; they are part of determining whether a setting can respond appropriately to complexity.
International visitors can ask for a plain-language description of on-site supervision, overnight observation, vital-sign monitoring, staffing coverage, transfer criteria, and the route to emergency services. The World Health Organization describes patient safety as the absence of preventable harm and the reduction of unnecessary risk; its patient safety guidance supports asking how risks are recognized and escalated in practice.
Useful questions focus on operational detail: Is a clinician physically present throughout monitoring? What equipment is available? Who makes the decision to transfer? Which emergency facility is used if needed? How is language access handled during an emergency? Vague answers should be treated as information, not filled in with assumptions.
“Emergency preparedness is not a marketing feature. It is the ability to name the plan, the people responsible, and the limits of what can be managed on site.”
04 · Leaving with a plan
Discharge should not be the end of the safety conversation.
Travel, fatigue, medication changes, emotional distress, and limited local support can all complicate the period after a stay. An adequate plan should be understandable before arrival, not improvised on the way out.
Readiness for discharge
Ask what observations or assessments inform discharge, who communicates remaining concerns, and how a visitor’s ability to travel is considered. A plan should acknowledge that a person may need more time or a higher level of care than expected.
Follow-up and handoff
Ask what written information is provided, what symptoms require urgent attention, how follow-up is coordinated, and how an existing physician or therapist can receive relevant information with consent.
Support after return
Consider whether a trusted support person knows the plan, whether transportation and lodging are stable, and whether local care is available if new symptoms or distress emerge after travel.
Clear boundaries
A responsible program should be direct about what it can and cannot manage. For a broader set of questions to take into provider conversations, see the clinic evaluation framework.
A practical standard
Look for clarity, documentation, and restraint.
Safety claims deserve follow-up questions. Screening, monitoring, emergency planning, and aftercare arrangements should be described in concrete terms and considered alongside a person’s own medical and psychiatric history. This guide does not provide dosing guidance, self-treatment protocols, or claims about efficacy.
Those researching neurological concerns may also encounter discussion at ibogaine and Alzheimer’s considerations; it remains important to distinguish exploratory discussion from established medical care and to seek individualized guidance from appropriately qualified professionals.